Respiratorius (RESP) Q3 2024 earnings summary

Executive summary

• No revenue generated in Q3 2024 or the nine-month period; focus remains on R&D and patent development.

• Net loss after financial items was -2,129 KSEK in Q3 2024, compared to -1,282 KSEK in Q3 2023.

• Patent for VAL001 formulation approved in the US, securing at least 20 years of market exclusivity from 2016.

• Strategic work to enhance VAL001 value and ongoing partner discussions supported by Q2 2024 rights issue proceeds.

Financial highlights

• Q3 2024 net sales: 0 KSEK (unchanged year-over-year); net loss after financial items: -2,129 KSEK (-1,282 KSEK in Q3 2023).

• EPS for Q3 2024: -0.004 SEK (unchanged year-over-year); nine-month EPS: -0.011 SEK (-0.018 SEK in 2023).

• Cash and cash equivalents at period end: 9,008 KSEK (2,890 KSEK in Q3 2023).

• Equity ratio at 97.89% as of September 30, 2024 (97.05% in Q3 2023).

• Rights issue in Q2 2024 provided 10,877 KSEK in new capital.

Outlook and guidance

• Liquidity is secured through 2025, enabling continued strategic and regulatory development activities.

• Ongoing partner negotiations for VAL001, aiming for a licensing or collaboration agreement.